Transmitted HIV drug resistance in Asia

Current Opinion in HIV and AIDS

Volumn 8, Issue 1, 2013, Pages 27-33

  Sohn, Annette H ^a   Srikantiah, Padmini ^b   Sungkanuparph, Somnuek ^c   Zhang, Fujie ^d  

^a Foundation for AIDS Research   (Thailand)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

antiretroviral therapy; Asia; HIV drug resistance; transmitted resistance; treatment failure

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ASIA; CAMBODIA; CHINA; DISEASE SURVEILLANCE; GENE MUTATION; GENOTYPE; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INDONESIA; MALAYSIA; PHILIPPINES; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SOCIOECONOMICS; SYSTEMATIC REVIEW (TOPIC); THAILAND; VIET NAM; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ASIA; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT FAILURE;

EID: 84871925702     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835b804f     Document Type: Review

References (43)

1. WHO. Global HIV/AIDS response-epidemic update and health sector progress towards Universal Access, Progress Report 2011. http://whqlib doc.who.int/publications/2011/9789241502986-eng.pdf [Accessed 13 August 2012].
2. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and metaregression analysis. Lancet 2012; 380:1250-1258.
3. Segeral O, Limsreng S, Nouhin J, et al.Short communication: three years followup of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment. AIDS Res Hum Retroviruses 2011; 27:597-603.
4. WHO. WHO HIV Drug Resistance Report 2012. http://apps.who.int/iris/ bitstream/10665/75183/1/9789241503938-eng.pdf [Accessed 13 August 2012].
5. Johnson VA, Calvez V, Gunthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top HIV Med 2011; 19:156-164.
6. Stanford University. HIV drug resistance database HIVdb program. http://hivdb.stanford.edu. [Accessed 13 August 2012].
7. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724.
8. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-223. (Pubitemid 46036930)
9. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13 (Suppl 2):1-13. (Pubitemid 352019085)
10. Duc NB, Hien BT, Wagar N, et al. Surveillance of transmitted HIV drug resistance using matched plasma and dried blood spot specimens from voluntary counseling and testing sites in Ho Chi Minh City, Vietnam, 2007-2008. Clin Infect Dis 2012; 54 (Suppl 4):S343-S347.
11. Hingankar NK, Thorat SR, Deshpande A, et al. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. Clin Infect Dis 2012; 54 (Suppl 4):S348-S354.
12. Liao L, Xing H, Dong Y, et al. Surveys of transmitted HIV drug resistance in 7 geographic Regions in China, 2008-2009. Clin Infect Dis 2012; 54 (Suppl 4):S320-S323.
13. Parkin N, Bremer J, Bertagnolio S. Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010. Clin Infect Dis 2012; 54 (Suppl 4):S266-S272.
14. WHO. WHO HIVDR Laboratory Network Annual Report for 2010. http://www.who.int/entity/hiv/topics/drugresistance/who-hivdr-lab oratory-net work-annual-report-2010.pdf [Accessed 13 August 2012].
15. Hamers RL, Oyomopito R, Kityo C, et al. Cohort profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol 2012; 41:43-54.
16. Land S, Cunningham P, Zhou J, et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods 2009; 159:185-193.
17. Sungkanuparph S, Oyomopito R, Sirivichayakul S, et al. HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia studies to evaluate resistance-monitoring study. Clin Infect Dis 2011; 52:1053-1057.
18. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2008. Top HIV Med 2008; 16:138-145.
19. Lai CC, Hung CC, Chen MY, et al. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother 2012; 67:1254-1260.
20. Chen IT, Lee BY, Lin PS, et al. The risk factor and prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in Southern Taiwan [Abstract #MOPE150]. 6th IAS Conference on HIV Pathogenesis and Treatment; 17-20 July 2011; Rome, Italy. http://www.iasociety. org/Default.aspx?pageId=11&abstractId=200741426 [Accessed 13 August 2012].
21. Wong KH, Chan WK, Yam WC, et al. Stable and low prevalence of transmitted HIV type 1 drug resistance despite two decades of antiretroviral therapy inHong Kong. AIDS Res Hum Retroviruses 2010; 26:1079-1085.
22. Gatanaga H, Ibe S,Matsuda M, et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res 2007; 75:75-82. (Pubitemid 46610525)
23. Hattori J, Shiino T, Gatanaga H, et al., and the Japanese Drug Resistance HIV-1 Surveillance Network. Surveillance of drug resistance and phylodynamic network analysis of newly infected HIV/AIDS patients: Japan, 2003 to 2010 [Paper #729]. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, Washington. http://www.retroconference. org/2012b/Abstracts/ 44128.htm [Accessed 13 August 2012].
24. Hattori J, Shiino T, Gatanaga H, et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res 2010; 88:72-79.
25. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl.pdf [Accessed 13 August 2012].
26. Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 (Suppl 2):25-36. (Pubitemid 352019087)
27. Kiertiburanakul S, Chaiwarith R, Sirivichayakul S, et al., on behalf of the TREAT Asia Studies to EvaluateResistance (TASER).Comparisons of primary HIVdrug resistance mutations between recent and chronic HIV infection among Asian patients [Paper #740]. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, Washington. http://www.retroconferen ce.org/2012b/Abstracts/44346.htm [Accessed 13 August 2012].
28. Ma Y, Zhang F, Li H, et al. Monitoring HIV drug resistance using early warning indicators in China: results from a pilot survey conducted in 2008. Clin Infect Dis 2012; 54 (Suppl 4):S300-S302.
29. Wang X, He C, Xing H, et al. Emerging transmitted HIV drug resistance mutations among HIV infected patients prior to start of first-line ART in multiple sites across China. AIDS Res Hum Retroviruses 2012 [Epub ahead of print].
30. Liao L, Xing H, Shang H, et al. The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 2010; 53 (Suppl 1):S10-S14.
31. Ye JR, Lu HY, Wang WS, et al. The prevalence of drug resistance mutations among treatment-naive HIV-infected individuals in Beijing, China. AIDS Res Hum Retroviruses 2012; 28:418-423.
32. National AIDS Control Organisation Department of AIDS Control. Patients alive and on ART. http://www.nacoonline.org/upload/HIV data/Patients alive and on ART-jan-2012.pdf [Accessed 13 August 2012].
33. National AIDS Control Organisation, Department of AIDS Control, Ministry of Health & Family Welfare. Annual Report 2010-11. http://www.nacoonline. org/upload/REPORTS/NACO Annual Report 2010-11.pdf [Accessed 13 August 2012].
34. Thorat SR, Chaturbhuj DN, Hingankar NK, et al. Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India. AIDS Res Hum Retroviruses 2011; 27:1291-1297.
35. Thai Ministry of Public Health, Thai National Coalition on AIDS, Thai Network of People living with HIV/AIDS, UNAIDS. Thailand AIDS Response Progress Report 2012, reporting period: 2010-2011. http://www.aidsdatahub.org/en/ reference-librarycols2/item/24202-ungass-country-progress-report-thai land-national-aids-committee-thailand-2012. [Accessed 13 August 2012].
36. Family Health International, Thai Ministry of Public Health. The Asian Epidemic Model (AEM) projections for HIV/AIDS in Thailand: 2005-2025. http://aids datahub.org/en/component/k2/item/23669-the-asian-epidemic-model- aemprojections-for-hiv/aids-in-thailand-2005-2025-fhi-analysis-and- advocacyproject-and-bureau-of-aids-tb-and-stis-department-of-disease-control- ministryof-public-health-thailand-2008 [Accessed 13 August 2012].
37. Sirivichayakul S, DeLong A,Wongkunya R, et al. Increasing HIV drug resistance among recently infected treatment-na?̈ve MSM in Thailand: results from three years of annual surveillance [Abstract#MOPE053]. 6th IASConference on HIV Pathogenesis and Treatment; 17-20 July 2011; Rome, Italy. http://www.iaso ciety.org/Default.aspx?pageId1/4;11&abstractId1/4;200742908 [Accessed 13 August 2012].
38. Sungkanuparph S, Sukasem C, Kiertiburanakul S, et al. Emergence of HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. J Int AIDS Soc 2012; 15:12.
39. Hoare A, Kerr SJ, Ruxrungtham K, et al. Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS One 2010; 5:e10981.
40. Vietnam AIDS Response Progress Report 2012. Following up the 2011 political declaration on HIV/AIDS. Reporting period: January 2010-December
41. Dean J, Ta Thi TH, Dunford L, et al. Prevalence of HIV type 1 antiretroviral drug resistance mutations in Vietnam: a multicenter study. AIDS Res Hum Retroviruses 2011; 27:797-801.
42. Tran VT, Ishizaki A, Nguyen CH, et al. No increase of drug-resistant HIV type 1 prevalence among drug-naive individuals in northern Vietnam. AIDS Res Hum Retroviruses 2012; 28:1349-1351.
43. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068.